Yong Kong
YOU?
Author Swipe
View article: Microbiome signatures of <i>Clostridioides difficile</i> toxin production and toxin gene presence: a shotgun metagenomic approach
Microbiome signatures of <i>Clostridioides difficile</i> toxin production and toxin gene presence: a shotgun metagenomic approach Open
Clostridioides difficile is an opportunistic gastrointestinal pathogen capable of asymptomatic colonization and causes diseases ranging from diarrhea to pseudomembranous colitis. Accurate diagnosis of C. difficile infection (CDI) is challe…
View article: High MGMT expression identifies aggressive colorectal cancer with distinct genomic features and immune evasion properties
High MGMT expression identifies aggressive colorectal cancer with distinct genomic features and immune evasion properties Open
Introduction The epigenetic silencing of O 6 -methylguanine DNA methyltransferase ( MGMT ) is associated with reduced DNA repair capacity, carcinogenesis and increased sensitivity to alkylating chemotherapy. However, the biological role an…
View article: Beyond von Mises Truss Models: Emergent Bistability in Mechanical Metamaterials
Beyond von Mises Truss Models: Emergent Bistability in Mechanical Metamaterials Open
We observe and analyze the phenomenon of bistability emergent from cooperative stiffening in hyper-elastic metamaterials. Using experimental and numerical results of identical geometric designs, we show evidence that a single unit is unist…
View article: Host-pathogen interaction profiling of nontypeable <i>Haemophilus influenzae</i> and <i>Moraxella catarrhalis</i> coinfection of bronchial epithelial cells
Host-pathogen interaction profiling of nontypeable <i>Haemophilus influenzae</i> and <i>Moraxella catarrhalis</i> coinfection of bronchial epithelial cells Open
Chronic obstructive pulmonary disease (COPD) is a progressive inflammatory lung disease and the third leading cause of death globally. Nontypeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) are common pathogens in indiv…
View article: Protective Evidence for Alcohol Consumption in Parkinson’s Disease Risk and Associated Genes of DPP6, SLC39A8, MAD1L1, and RBFOX1
Protective Evidence for Alcohol Consumption in Parkinson’s Disease Risk and Associated Genes of DPP6, SLC39A8, MAD1L1, and RBFOX1 Open
Background Parkinson’s disease (PD), a leading neurodegenerative disorder, is increasing in prevalence globally due to population ageing. Although alcohol consumption is widespread worldwide, its role in PD pathogenesis remains contentious…
View article: Cutaneous Lupus Features Specialized Stromal Niches and Altered Retroelement Expression
Cutaneous Lupus Features Specialized Stromal Niches and Altered Retroelement Expression Open
View article: Prospective comparison of the digestive tract resistome and microbiota in cattle raised in grass-fed versus grain-fed production systems
Prospective comparison of the digestive tract resistome and microbiota in cattle raised in grass-fed versus grain-fed production systems Open
Most antimicrobials sold in the United States are used in food animals. Farm management practices contribute to antibacterial resistance (AR). Controversially, grass-fed diets have been recommended over grain-fed diets to reduce AR in beef…
View article: Harmonically Induced Shape Morphing of Bistable Buckled Beam with Static Bias
Harmonically Induced Shape Morphing of Bistable Buckled Beam with Static Bias Open
We investigate the effect of a constant static bias force on the dynamically induced shape morphing of a pre-buckled bistable beam, focusing on the beam's ability to change its vibration to be near different stable states under harmonic ex…
View article: Adventitious angles problem: the lonely fractional derived angle
Adventitious angles problem: the lonely fractional derived angle Open
In the "classical" adventitious angle problem, for a given set of three\nangles $a$, $b$, and $c$ measured in integral degrees in an isosceles triangle,\na fourth angle $\\theta$ (the derived angle), also measured in integral degrees,\nis …
View article: Genomic evidence of sex chromosome aneuploidy and infection-associated genotypes in the tsetse fly Glossina fuscipes, the major vector of African trypanosomiasis in Uganda
Genomic evidence of sex chromosome aneuploidy and infection-associated genotypes in the tsetse fly Glossina fuscipes, the major vector of African trypanosomiasis in Uganda Open
The primary vector of the trypanosome parasite causing human and animal African trypanosomiasis in Uganda is the riverine tsetse fly Glossina fuscipes fuscipes (Gff). Our study improved the Gff genome assembly with whole genome 10× Chromiu…
View article: Correction: Sha et al. Differences in Root Endophytic Bacterial Communities of Chinese Cork Oak (Quercus variabilis) Seedlings in Different Growth Years. Forests 2023, 14, 1489
Correction: Sha et al. Differences in Root Endophytic Bacterial Communities of Chinese Cork Oak (Quercus variabilis) Seedlings in Different Growth Years. Forests 2023, 14, 1489 Open
There was an error in the last sentence in part “2.1. Study Area and Sample Collection”, and the first sentence in “2.3. DNA Extraction and PCR Amplification” in the original publication [...]
View article: Differences in Root Endophytic Bacterial Communities of Chinese Cork Oak (Quercus variabilis) Seedlings in Different Growth Years
Differences in Root Endophytic Bacterial Communities of Chinese Cork Oak (Quercus variabilis) Seedlings in Different Growth Years Open
In forests, seedling renewal is influenced by many environmental factors, including climate change, seed size, wildfires, and ecological factors. It is unclear how different growth years of seedlings affect Chinese cork oak (Quercus variab…
View article: Supplementary Figure 4 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer
Supplementary Figure 4 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer Open
Supplementary Figure 4: The change in PBMCs for patients with clinical benefit (blue) and no benefit (red).
View article: Supplementary Figure 2 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer
Supplementary Figure 2 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer Open
Supplementary Figure 2: Molecular Analysis
View article: TABLE 1 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer
TABLE 1 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer Open
Baseline characteristics
View article: Supplementary Figure 3 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer
Supplementary Figure 3 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer Open
Supplementary Figure 3: Changes in MGMT expression, yH2AX and CD8+ T cells in pre-treatment and post-treatment biopsies of patients who derived clinical benefit from the trial.
View article: Data from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer
Data from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer Open
Purpose:O6-methylguanine DNA methyltransferase (MGMT)-silenced tumors reveal sensitivity to temozolomide (TMZ), which may be enhanced by PARP inhibitors. Approximately 40% of colorectal cancer has MGMT silencing an…
View article: Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer
Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer Open
Purpose: O6-methylguanine DNA methyltransferase (MGMT)-silenced tumors reveal sensitivity to temozolomide (TMZ), which may be enhanced by PARP inhibitors. Approximately 40% of colorectal cancer has MGMT silencing and we aimed to measure an…
View article: Supplementary Methods 1 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer
Supplementary Methods 1 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer Open
Supplementary Methods 1: Clinical trial protocol.
View article: Supplementary Table 2 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer
Supplementary Table 2 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer Open
Supplementary Table 2: A classification of the immune cell subtypes.
View article: Supplementary Methods 1 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer
Supplementary Methods 1 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer Open
Supplementary Methods 1: Clinical trial protocol.
View article: Supplementary Figure 3 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer
Supplementary Figure 3 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer Open
Supplementary Figure 3: Changes in MGMT expression, yH2AX and CD8+ T cells in pre-treatment and post-treatment biopsies of patients who derived clinical benefit from the trial.
View article: Supplementary Table 1 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer
Supplementary Table 1 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer Open
Supplementary Table 1: Study representativeness table.
View article: Supplementary Figure 4 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer
Supplementary Figure 4 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer Open
Supplementary Figure 4: The change in PBMCs for patients with clinical benefit (blue) and no benefit (red).
View article: TABLE 2 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer
TABLE 2 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer Open
Frequency of treatment-related adverse events and laboratory abnormalities
View article: TABLE 1 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer
TABLE 1 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer Open
Baseline characteristics
View article: Supplementary Table 1 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer
Supplementary Table 1 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer Open
Supplementary Table 1: Study representativeness table.
View article: TABLE 2 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer
TABLE 2 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer Open
Frequency of treatment-related adverse events and laboratory abnormalities
View article: Data from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer
Data from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer Open
Purpose:O6-methylguanine DNA methyltransferase (MGMT)-silenced tumors reveal sensitivity to temozolomide (TMZ), which may be enhanced by PARP inhibitors. Approximately 40% of colorectal cancer has MGMT silencing an…
View article: Supplementary Figure 1 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer
Supplementary Figure 1 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer Open
Supplementary Figure 1: Survival Analysis.